Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

All Presentations Include New Data from the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution in Autoimmune Pulmonary Alveolar Proteinosis

Apr. 15, 2026 at 4:51am

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image revealing the delicate internal structures of a human lung, conceptually illustrating the advanced medical research into rare respiratory conditions.Cutting-edge medical imaging techniques offer a rare glimpse into the intricate workings of the lungs, providing critical insights for advancing treatments for rare respiratory diseases.Cincinnati Today

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations at the ATS International Conference in Orlando, Florida, May 17-20, 2026. The presentations will include new data from the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP), including data from the ongoing open-label treatment period.

Why it matters

aPAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli, leading to impaired gas exchange and serious complications. Savara's lead program, molgramostim inhalation solution, is in Phase 3 development as a potential treatment for aPAP, and the new data being presented at ATS 2026 could provide important insights into the efficacy and safety of this investigational therapy.

The details

The oral presentation will focus on how molgramostim improved exercise distance and duration in patients with aPAP, while the two poster presentations will cover the long-term efficacy and safety of molgramostim, as well as the relationship between pulmonary gas transfer and biomarker levels in aPAP patients. Additionally, Savara will host an industry theater session on advances in aPAP, featuring expert discussions on the pathophysiology, clinical presentation, diagnosis, and management of the disease.

  • The ATS International Conference will take place from May 17-20, 2026 in Orlando, Florida.
  • The oral presentation is scheduled for Monday, May 18, 2026 from 2:51 - 3:03 PM EDT.
  • The first poster presentation is scheduled for Tuesday, May 19, 2026 from 2:15 - 4:15 PM EDT.
  • The second poster presentation is scheduled for Wednesday, May 20, 2026 from 8:15 - 10:15 AM EDT.
  • The industry theater session is scheduled for Monday, May 18, 2026 from 1:00 - 2:00 PM EDT.

The players

Savara Inc.

A clinical stage biopharmaceutical company focused on rare respiratory diseases, and the sponsor of the IMPALA-2 clinical trial of molgramostim inhalation solution in aPAP.

Cormac McCarthy, M.D., Ph.D., FRCPI

Associate Professor of Medicine at University College Dublin (UCD) and Consultant Respiratory Physician at St. Vincent's University Hospital in Dublin, Ireland. He will be the presenter for the oral presentation at the ATS conference.

Bruce Trapnell, M.D.

Professor of Medicine and Pediatrics at the University of Cincinnati College of Medicine. He will be the presenter for one of the poster presentations at the ATS conference.

Yoshikazu Inoue, M.D., Ph.D.

Executive Director of the Clinical Research Center at NHO Kinki Chuo Chest Medical Center and Internal Medicine at Osaka Anti-Tuberculosis Association Osaka Fukujuji Hospital in Osaka, Japan. He will be the presenter for the other poster presentation at the ATS conference.

Kevin Davidson, M.D., FCCP

He will present an update on aPAP, addressing pathophysiology, clinical presentation, diagnosis, and management, during the Savara industry theater session at the ATS conference.

Jeff Sippel, M.D.

He will moderate the discussion during the Savara industry theater session at the ATS conference, incorporating insights from his clinical experience and the lived experience of a patient advocate living with aPAP.

Kelsea A.

A patient advocate living with aPAP, who will share her lived experience during the Savara industry theater session at the ATS conference.

Got photos? Submit your photos here. ›

What they’re saying

“Molgramostim Improves Exercise Distance and Duration in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Phase 3 Clinical Trial”

— Cormac McCarthy, M.D., Ph.D., FRCPI, Associate Professor of Medicine, University College Dublin (UCD) and Consultant Respiratory Physician, St. Vincent's University Hospital, Dublin, Ireland

“Long-term Efficacy and Safety of Molgramostim in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Trial Open-Label Treatment Period”

— Bruce Trapnell, M.D., Professor of Medicine and Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH

“Relationship Between Pulmonary Gas Transfer and Biomarker Levels in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)”

— Yoshikazu Inoue, M.D., Ph.D., Executive Director of the Clinical Research Center, NHO Kinki Chuo Chest Medical Center and Internal Medicine, Osaka Anti-Tuberculosis Association Osaka Fukujuji Hospital, Osaka, Japan

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

The new data being presented at the ATS 2026 International Conference on Savara's molgramostim inhalation solution could provide important insights into the potential of this investigational therapy to address the significant unmet need for effective treatments for the rare and debilitating lung disease, autoimmune pulmonary alveolar proteinosis.